临床试验/NCT01267266

NCT01267266终止2 期

A Randomized Discontinuation Phase 2 Study of AZD0530 as a Metastasis Inhibitor in Castrate Resistant Prostate Cancer

National Cancer Institute (NCI)15 个研究点分布在 1 个国家目标入组 31 人开始时间: 2010年12月最近更新: 2015年4月1日

适应症

干预措施

试验速览

阶段: 2 期
状态: 终止
发起方: National Cancer Institute (NCI)
入组人数: 31
试验地点: 15
主要终点: Duration of Stable Disease. (Time to Disease Progression by CT and/or Bone Scan or Clinical Progression.)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This randomized phase II clinical trial is studying how well saracatinib works in treating patients with prostate cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

详细描述

PRIMARY OBJECTIVES:

I. Determine if AZD0530 (saracatinib) increases time to radiographic progression in men with CRPC compared to placebo.

SECONDARY OBJECTIVES:

I. Describe the adverse events related to AZD0530 in this population. II. Explore the role of FYN and other SRC kinase expression as a predictor of response to AZD0530.

OUTLINE: This is a multicenter study.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

性别: Male
接受健康志愿者: 否

入选标准

•Histologically or cytologically confirmed prostate cancer with progressive disease; progressive disease may be defined as either
•New clinical or radiographic metastases
•Rising PSA: PSA must be greater than 1.0 ng/mL with at least 2 consecutive rises after completion of prior therapy; the PSA values documenting these rises should be separated by no less than 10 days; the baseline PSA value may be taken from the end of prior therapy
•Previous treatment with docetaxel for disease progression following hormonal therapy (i.e., castrate-resistant disease) required
•Treatment in the adjuvant or neoadjuvant setting will NOT be grounds for inclusion unless docetaxel has been used again in the setting of progressive CRPC
•ECOG performance status 0-1
•ANC ≥ 1,500/mm³
•Hemoglobin > 9.0 g/dL
•Platelet count > 100,000/mm³
•Total bilirubin < 2.0 x institutional ULN
•AST/ALT < 5 x institutional ULN in the presence of bone/liver metastases
•Serum creatinine (Cr) within ULN
•Patients with Cr > ULN must have a Cr clearance of > 60 mL/min
•Testosterone 50 ng/mL or lower if a patient is receiving an LHRH agonist
•No testosterone testing is required for men who have undergone surgical orchiectomy
•Fertile patients must agree to abstinence or some adequate form of contraception
•No patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs the ability to swallow AZD0530 tablets
•No history of uncontrolled or unstable cardiac dysrhythmia
•No resting ECG with measurable QTc interval of > 480 msec at 2 or more time points within a 24-hour period
•No evidence of interstitial lung disease (bilateral, diffuse, parenchymal lung disease)
•A high-resolution CT of the chest will be required during screening
•No evidence of severe or uncontrolled systemic conditions (e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol
•No patients with a known immunodeficiency syndrome
•No patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD0530
•No patients receiving any other investigational agents
•Previous AZD0530 exposure is allowed provided that the patient did not show radiographic progression during treatment
•Patients receiving non-steroidal anti-androgens (e.g., flutamide) or other hormonal treatment (such as ketoconazole, abiraterone, or TAK-700) must have stopped these drugs at least 28 days prior to enrollment for flutamide or ketoconazole, or at least 42 days prior to enrollment for bicalutamide or nilutamide, and the patients must have demonstrated progression of disease since the agents were suspended
•Patients should be at least 2 weeks away from previous chemotherapy, surgery, or radiotherapy
•No unresolved toxicity from previous treatments that are CTCAE grade 2 from previous anti-cancer therapy (except alopecia)
•Patients who are currently on zoledronic acid (Zometa) or other bisphosphonate therapy are eligible provided that they have been on therapy at least 6 weeks prior to participation
•Increases in bisphosphonate dosing will not be allowed (i.e., starting within 6 weeks or changing from every 3-month to every 1-month dosing)
•Use of specifically prohibited CYP3A4-active agents or substances are not permitted during protocol treatment, and patients who must continue treatment with these agents are not eligible
•Prohibited drugs should be discontinued 7 days prior to the administration of the first dose of AZD0530 and for 7 days following discontinuation of AZD0530 (unless otherwise specified)
•No concurrent use of non-FDA approved medications

排除标准

未提供

研究组 & 干预措施

Arm I (saracatinib)

Experimental

Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

干预措施: saracatinib (Drug)

Arm II (placebo)

Placebo Comparator

Patients receive oral placebo once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Upon progression, patients may crossover to arm I.

干预措施: hydrocortisone/placebo (Other)

结局指标

主要结局

Duration of Stable Disease. (Time to Disease Progression by CT and/or Bone Scan or Clinical Progression.)

时间窗: Up to 6 months.

Time to progression will be assessed using the Kaplan-Meier method and compared between groups via Wilcoxon rank-sum test.

次要结局

Toxicity and Incidence of Adverse Events.(Up to 6 months.)
Toxicity and Incidence of Adverse Events(Up to 6 months.)
Correlation of Molecular Profile With Clinical Outcomes(Up to 2 years)

研究者

发起方

National Cancer Institute (NCI)

申办方类型

Nih

责任方

Sponsor

研究点 (15)

Loading locations...

相似试验

已完成

2 期

AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination ChemotherapyRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer

NCT00638937National Cancer Institute (NCI)37

终止

2 期

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic CancerInvasive Thymoma and Thymic CarcinomaRecurrent Thymoma and Thymic CarcinomaStage III ThymomaStage IVA ThymomaStage IVB Thymoma

NCT00718809National Cancer Institute (NCI)21

已完成

2 期

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic CancerAdenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic Cancer

NCT00735917National Cancer Institute (NCI)19

已完成

2 期

NCT00513435National Cancer Institute (NCI)9

已完成

2 期

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction CancerAdenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the StomachRecurrent Gastric CancerStage III Gastric CancerStage III Esophageal CancerStage IV Esophageal CancerStage IV Gastric Cancer

NCT00607594National Cancer Institute (NCI)21